Massive study checks if PCV20 vaccine stops pneumonia in At-Risk adults
NCT ID NCT07251465
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at health records of over 800,000 adults to see if the PCV20 vaccine reduces pneumonia cases. Researchers will compare pneumonia rates in people who got the vaccine versus those who did not. The goal is to measure how effective PCV20 is in adults aged 18 and older with conditions that raise their risk for pneumococcal disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PCV20 vaccine
- What this could lead to
- If effective, this could confirm that PCV20 helps prevent pneumonia in adults with higher risk, supporting its wider use.
- What could go wrong
- This is an observational study using existing records, not a controlled trial. Results may be affected by unmeasured differences between vaccinated and unvaccinated groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?
- Can a simple inhaled combo keep pneumonia patients off ventilators?